Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint molecules evolved to prevent self-attack by T cells.
• Cancer cells exploit these checkpoints to evade immune responses.
• Blocking immune checkpoints enhances anti-tumor immunity.

Purpose of the Study:

• Review advancements in immune checkpoint molecule research.
• Discuss the application of blocking antibodies in cancer therapy.
• Analyze cardiac toxicity associated with these therapies and management strategies.

Main Methods:

• Literature review of immune checkpoint inhibitors in cancer treatment.
• Analysis of clinical trial data and FDA-approved checkpoint inhibitors.
• Review of studies on immune-related adverse events, focusing on cardiac toxicity.

Main Results:

• Immune checkpoint inhibitors (e.g., CTLA-4, PD-1) significantly improve outcomes in advanced cancers.
• These therapies can lead to immune-related adverse events (irAEs) affecting multiple organs.
• Cardiac toxicity is a notable and potentially fatal irAE.

Conclusions:

• Immune checkpoint inhibitors represent a major advancement in cancer therapy.
• Effective monitoring and management of irAEs, particularly cardiac events, are crucial.
• Further research is needed to optimize safety and efficacy.